Longboard Pharmaceuticals, Inc., (LBPH): Price and Financial Metrics
LBPH Price/Volume Stats
| Current price | $18.20 | 52-week high | $28.15 |
| Prev. close | $18.01 | 52-week low | $3.60 |
| Day low | $17.69 | Volume | 24,320 |
| Day high | $18.20 | Avg. volume | 1,310,634 |
| 50-day MA | $20.09 | Dividend yield | N/A |
| 200-day MA | $11.58 | Market Cap | 655.51M |
LBPH Stock Price Chart Interactive Chart >
Longboard Pharmaceuticals, Inc., (LBPH) Company Bio
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.
Latest LBPH News From Around the Web
Below are the latest news stories about LONGBOARD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LBPH as an investment opportunity.
Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy VolunteersLA JOLLA, Calif., November 29, 2023--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the initiation of a Phase 1 randomized, double-blind, placebo-controlled, SAD clinical study of LP659. LP659 is an oral, centrally acting, next-generation sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator in development for the potential treatment of rare neu |
Down -25.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Longboard Pharmaceuticals, Inc. (LBPH)Longboard Pharmaceuticals, Inc. (LBPH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy CommunityLA JOLLA, Calif., November 21, 2023--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data for LP352, a novel, highly selective investigational treatment in development for seizures associated with a range of Developmental and Epileptic Encephalopathies (DEEs), in poster sessions at the 2023 AES Annual Meeting. Longboard will also host a |
Farallon Capital: A Global and Diversified Hedge Fund and its Top Stock PicksIn this article, we discuss Farallon Capital: a global and diversified hedge fund and its top stock picks. If you want to skip our detailed analysis of these stocks, go directly to the Top 5 Stock Picks of Farallon Capital. Risk arbitrage or merger arbitrage is one of the most popular strategies that hedge funds […] |
Wall Street Analysts Believe Longboard Pharmaceuticals, Inc. (LBPH) Could Rally 262.45%: Here's is How to TradeThe consensus price target hints at a 262.5% upside potential for Longboard Pharmaceuticals, Inc. (LBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
LBPH Price Returns
| 1-mo | -11.48% |
| 3-mo | -25.50% |
| 6-mo | 279.17% |
| 1-year | 147.28% |
| 3-year | 79.49% |
| 5-year | N/A |
| YTD | 201.82% |
| 2023 | 84.97% |
| 2022 | -33.20% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...